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ABSTRACT
INTRODUCTION Radiofrequency ablation (RFA) of outflow tract ventricular arrhythmia (VA) that origi‑
nates from the aortic cusps can be challenging. Data on long ‑term efficacy and safety as well as optimal 
technique after aortic cusp ablation have not previously been reported.
OBJECTIVES This aim of the study was to determine the short‑ and long ‑term outcomes after RFA of 
aortic cusp VA, and to evaluate aortic valve injuries according to echocardiographic screening.
PATIENTS AND METHODS This was a prospective multicenter registry (AVATAR, Aortic Cusp Ventricular 
Arrhythmias: Long Term Safety and Outcome from a Multicenter Prospective Ablation Registry) study. 
A total of 103 patients at a mean age of 56 years (34–64) from the “Electra” Registry (2005–2017) 
undergoing RFA of aortic cusps VA were enrolled. The following 3 ablation techniques were used: zero‑
‑fluoroscopy (ZF; electroanatomical mapping [EAM] without fluoroscopy), EAM with fluoroscopy, and 
conventional fluoroscopy ‑based RFA. Data on clinical history, complications after RFA, echocardiography, 
and 24 ‑hour Holter monitoring were collected. The follow ‑up was 12 months or longer.
RESULTS There were no major acute cardiac complications after RFA. In one case, a vascular access 
complication required surgery. The median (interquartile range [IQR]) procedure time was 75 minutes 
(IQR, 58–95), median follow ‑up, 32 months (IQR, 12–70). Acute and long ‑term procedural success rates 
were 93% and 86%, respectively. The long ‑term RFA outcomes were observed in ZF technique (88%), 
EAM with fluoroscopy (86%), and conventional RFA (82%), without differences. During long ‑term follow‑
‑up, no abnormalities were found within the aortic root.
CONCLUSIONS Ablation of VA within the aortic cusps is safe and effective in long ‑term follow ‑up. The ZF 
approach is feasible, although it requires greater expertise and more imaging modalities.
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a 1 ‑year or longer observation after the last ab‑
lation. The patients were informed on follow‑
‑up appointment schedule and were contacted 
to schedule echocardiography and 24 ‑h Holter 
monitoring. Clinical data on follow ‑up, compli‑
cations, and postablation antiarrhythmic drugs 
were collected. A standardized definition of ma‑
jor complications was used as shown in Supple‑
mentary material, Table S1.
Mapping and ablation protocol We analyzed 3 tech‑
niques: zero ‑fluoroscopy (ZF) (3D ‑EAM without 
fluoroscopy), 3D ‑EAM with fluoroscopy, and con‑
ventional fluoroscopy ‑based ablation (without 
support of 3D ‑EAM system). The choice of tech‑
nique was at the discretion of the operator and 
was dependent on the availability of the 3D ‑EAM.
Local anesthesia and light conscious sedation 
were used in RFA. Ablation and diagnostic cath‑
eters (4 mm, 8 mm, or irrigated gold ‑tip cath‑
eters; Biotronik, Berlin, Germany or Tacticath, 
Abbott, St. Paul, Minnesota, United States) were 
introduced percutaneously via femoral access. 
In most cases, a standard decapolar diagnostic 
catheter was introduced into the coronary sinus 
or the right ventricle under fluoroscopic guid‑
ance or using the 3D ‑EAM system (Ensite Ve‑
locity NavX, St Jude Medical, St. Paul, Minne‑
sota, United States) with near zero–fluorosco‑
py or ZF. First, a programmed ventricular stim‑
ulation was conducted to assess the propensi‑
ty for sustained VA. Then, in most cases, classic 
right ventricular outflow tract (RVOT) mapping 
was performed to identify the optimum ablation 
site according to pace and local activation map‑
ping. If no adequate RVOT sites were identified 
or if RFA in RVOT was unsuccessful, the map‑
ping was extended to the LVOT. Left ventricular 
outflow tract sites were mapped via a retrograde 
aortic approach. If LVOT mapping was insuffi‑
cient, a mapping catheter was inserted through 
distal coronary sinus, in order to validate the sig‑
nals from the LVOT epicardial region, mapping 
the great cardiac vein and the left main ostium.7 
In patients without spontaneous ectopy at the 
time of intracardiac mapping, pacing or isopro‑
terenol infusions (or both) were used to induce 
PVCs or VT. The location of aortic cusps was de‑
termined with coronary angiography and angiog‑
raphy of the Valsalva sinuses. However, if ZF was 
used, the location of coronary artery ostia was 
identified with the use of 3D ‑EAM and separate 
visualization of aortic cusps, location of the re‑
cording of right and left His bundle, and intracar‑
diac signals. The position of ablation catheter tip 
within the aortic cusp was confirmed using several 
techniques (ie, inability to move further through 
the aortic valve and to bend catheter to the mi‑
tral annulus). The example of near zero –fluoros‑
copy for aortic cusp ablation is shown in Supple‑
mentary material, Figure S1. Mapping methods 
included simple maps with aortic cusp or aortic 
root contours, activation mapping with unipolar 
recordings, and pace mapping up to maximum 
INTRODUCTION Radiofrequency catheter abla‑
tion (RFA) is a safe and effective method for treat‑
ing patients with idiopathic ventricular arrhyth‑
mias (IVA). Approximately 15% of IVA originate 
from the left ventricular outflow tract (LVOT) 
and can be mapped and ablated within the aor‑
tic root.1,2 However, aortic cusp catheter ablation 
is a challenging procedure due to the risk of aor‑
tic valve leaflet damage as well as close proximi‑
ty to coronary arteries and atrioventricular con‑
duction system.1,3 The 3 ‑dimensional electroana‑
tomical mapping (3D ‑EAM) system enables pre‑
cise reconstruction of aortic root anatomy and 
tracking the catheter position during ablation, 
thus avoiding X ‑ray exposure and coronary angi‑
ography.4 Currently, efficacy and safety data on 
aortic cusp ablation is limited, especially consid‑
ering the procedures based on 3D ‑EAM without 
fluoroscopy.2,4,5 Available data show that aortic 
cusp catheter ablation of IVA can be performed 
safely.1-5 Most analyses are retrospective, based 
on small patient samples, and not aimed direct‑
ly at excluding potential aortic valve injuries. No 
echocardiographic studies have documented long‑
‑term safety of RFA. Current European guide‑
lines cautiously recommend referring patients 
with suspected LVOT arrhythmias only to elec‑
trophysiology centers with experienced person‑
nel.6 Therefore, the aim of this prospective mul‑
ticenter registry study was to determine acute‑ 
and long ‑term outcomes and safety of aortic cusp 
ablation, especially ablations performed without 
fluoroscopy.
PATIENTS AND METHODS The study population 
included patients from a prospective multicenter 
“Electra” registry, which covered ablation proce‑
dures from 10 Polish centers. The majority of pro‑
cedures (74%) were performed by 5 experienced 
operators only, and 26% by 5 intermediate as‑
sistants under the guidance of experts. Patients 
undergoing aortic cusp RFA for frequent prema‑
ture ventricular complexes (PVCs) and / or ven‑
tricular tachycardia (VT) were recruited between 
2005 and 2017. All ablation procedures were done 
in line with the current guidelines6 after failure 
of medical treatment or directly in patients opt‑
ing out of long ‑term antiarrhythmic drug thera‑
py. IVA was diagnosed in patients without struc‑
tural heart disease (SHD), based on history, typ‑
ical clinical features, echocardiography, exercise 
stress testing, cardiac catheterization, and cardi‑
ac magnetic resonance imaging (MRI) when need‑
ed. Structural heart disease was defined as isch‑
emic or nonischemic cardiomyopathy, history of 
myocardial infarction (MI), revascularization, or 
significant (moderate or severe) valvular disease.
Baseline data included demographic charac‑
teristics, cardiac history, procedure details, echo‑
cardiography, and 24 ‑hour Holter monitoring. 
The acute‑ and short ‑term follow ‑up was set at the 
time of ablation procedure and 1 month after, 
respectively. Long ‑term follow ‑up extended be‑
tween September 2017 and May 2018 to ensure 
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hypothesis was verified using the Mann–Whitney 
test or t test. For categorical variables, the between‑
‑group differences were determined using the χ2 
or Fisher exact tests. The ablation details in re‑
spect to ablation cusp target with global P calcu‑
lation were compared using the Kruskal–Wallis 
test. The changes of continuous variables in time 
were compared using the paired samples t test for 
normally distributed data or using the Wilcoxon 
signed ‑rank test for data with skewed distribution. 
A P value of less than 0.05 was considered signifi‑
cant. No adjustment for multiple comparisons was 
made. All statistical analyses were performed us‑
ing the R 3.4 bundle (R Foundation for Statistical 
Computing, Vienna, Austria).
Ethic The study was conducted in accordance 
with the tenets of the Declaration of Helsinki. 
All patients provided written informed consent 
to participate in the study. The study protocol was 
approved by the local institutional ethics commit‑
tee (decision number 5/4/2017).
RESULTS Patient population Between 2005 and 
2017, 1163 patients underwent RFA due to IVA. 
Of those, 120 patients (10.3%) had aortic cusp 
ablation. Additionally, 305 patients with SHD re‑
quired RFA for VA. From the latter group, the ori‑
gin of PVC / VT was located within the aortic cusp 
in 19 patients (6.2%; IVA vs PVC / VT in SHD; 
P = 0.03). Among 139 patients undergoing RFA 
for aortic cusp VA, 45% were women, the mean 
(SD) age was 49.1 (19.7) years, and the mean (SD) 
baseline LVEF was 59% (8.9).
Acute procedural success was achieved in 94% 
of patients. During the long ‑term follow ‑up, 6 pa‑
tients died of causes unrelated to RFA. Another 30 
patients were lost to follow ‑up. Complete data on 
follow ‑up were available for 103 patients whose 
characteristics are shown in TABLE 1.
Compared with patients with IVA, those with 
PVCs / VT in SHD were older, had more comorbid‑
ities, lower LVEF, and a tendency toward a higher 
body mass index. Most patients had a single PVC 
configuration. Patients with PVC / VT in SHD were 
more frequently affected by complex arrhythmias 
(nonsustained VT) than patients with IVA. There 
were no differences in the number of antiarrhyth‑
mic drugs or follow ‑up duration.
Procedure details, short- and long -term out-
comes The majority of patients had VA arising 
from the LCC (48%); less frequent locations were 
AMC / LCC (26%), LCC / RCC (11%), RCC (9%), 
and NCC (6%). The median procedure duration 
was 75 minutes (IQR, 58–95), fluoroscopy time 
was 5 minutes (IQR, 0–16), and the number of 
RFA applications was 9 (IQR, 5–15). Pacemapping 
was available only in a minority of cases (18%); 
therefore, activation mapping was mainly used. 
Procedure details regarding VA cusp location are 
shown in TABLE 2.
There were differences in respect to age be‑
tween patients undergoing AMC / LCC ablation 
pacing thresholds of 25 mA with evaluation of 
12/12 pacing morphology when necessary. Radio‑
frequency ablation applications were set at 30W 
(for irrigated catheters) or 60W (for nonirrigat‑
ed catheters) at 48°C to 60°C.
The acute procedural success of RFA was de‑
fined as a  complete absence of spontaneous 
PVCs / VT for more than 15 minutes following 
the last application, noninducibility after iso‑
proterenol infusion, and complete electrophysi‑
ology study using atrial incremental pacing, and 
ventricular and atrial programmed pacing up to 
3 extra stimuli.
The origins of PVCs / VT were classified as left 
coronary cusp (LCC), right coronary cusp (RCC), 
LCC / RCC junction (LCC / RCC), noncoronary cusp 
(NCC), or aortomitral continuity (AMC) / LCC 
area, if both sites were required for successful 
ablation.
The origins of PVCs from epicardial left ven‑
tricular summit was suspected in each patient 
with unsuccessful procedure. They were offered 
the next procedure with epicardial access, yet 
none of the 3 patients who were suspected to 
have epicardial origin from inaccessible sites of 
left ventricular summit consented to subsequent 
procedure. Despite that, these patients were in‑
cluded in the study due to primary RFA performed 
in the LCC.
24 -hour Holter monitoring The 24 ‑hour Holter 
monitoring was obligatory prior to ablation and 
was repeated after 1 month and at the final follow‑
‑up visit in order to determine the PVC burden. 
Treatment success was referred to as 80% or high‑
er postablation decrease in PVC burden. In case 
of recurrent arrhythmias, 12 ‑channel ECG Holt‑
er monitoring was performed to validate arrhyth‑
mia and determine the PVC / VT morphology.
Transthoracic echocardiography Transthoracic 
echocardiogram was performed before and after 
ablation and was repeated after 1 month, at the fi‑
nal follow ‑up visit, or more frequently depending 
on clinical need. The aim of transthoracic echo‑
cardiogram at the final visit was to exclude aor‑
tic / mitral leaflet damage and assess left ventric‑
ular ejection fraction (LVEF). MRI was scheduled 
in cases of suspected pathologic lesions in aortic 
leaflets. Aortic pathologies were classified as ma‑
jor (significant aortic regurgitation / stenosis, leaf‑
let perforation) or minor (mild / moderate aortic 
regurgitation / stenosis, other cusp abnormali‑
ties). The specialists performed echocardiogra‑
phy according to relevant guidelines8 and were 
blinded to the aortic cusp ablation site. A base‑
line left ventricular ejection fraction more than 
50% was consistent with suspected PVC ‑induced 
cardiomyopathy.
Statistical methods Categorical variables were ex‑
pressed as numbers and percentages. Quantita‑
tive variables were expressed as medians and in‑
terquartile ranges (IQRs) or means (SD). The null 
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not significant (FIGURE 1). During the follow ‑up, 
8% patients underwent second ablation proce‑
dure and 3% required third ablation due to VA 
recurrence or procedural failure.
The ablation success was not SHD ‑dependent 
and was comparable in the IVA and SHD groups. 
The success rates for acute, short‑ and long ‑term 
follow ‑up were 92%, 81%, and 87%, respective‑
ly in the IVA group and 100%, 85%, and 80%, re‑
spectively in the SHD group.
and those with LCC, NCC, and RCC targets. 
Patients with VA originating from NCC were 
solely men and were younger than those in 
the AMC / LCC group.
Overall, acute, short ‑term, and long ‑term suc‑
cess was achieved after a mean of 1.1 procedures 
in 93%, 81%, and 86% of patients, respectively. 
The highest ablation success rate was noted for 
VA arising from the NCC and the lowest was for 
the AMC / LCC cusp target, yet the difference was 
TABLE 1 Patient characteristics
Parameter All IVA VA ‑SHD P value
Number 103 90 13 –
Age, y, median (IQR) 56 (34–64) 54.5 (33.2–63) 64 (62–69) <0.001
Women, % 48.5 50 38.5 0.63
Hypertension, % 61.2 56.7 92.3 0.03
Insulin ‑dependent diabetes, % 3.9 1.1 23.1 0.006
BMI, kg/m2, mean (SD) 26.9 (4.9) 26.6 (5) 29.0 (3.7) 0.06
LVEF before ablation, %, mean (SD) 58.3 (8.5) 59.9 (6.7) 44.9 (11.2) 0.004
PVC burden before ablation, %, median (IQR) 20 (12–30) 20 (12–30) 23.0 (17.5–29.2) 0.43
PVC / 24 hours, median (IQR) 19 670 
(11 688–29 904.5)
19 537 
(11 000–29 838)
23 335 
(18 157–29 231.2)
0.38
PVC, % 96.1 95.6 100 1.00
PVC / pairs, % 55.3 53.3 69.2 0.44
PVC / non sustained VT, % 29.1 24.4 61.5 0.02
PVC / VT, % 4.9 4.4 7.7 0.50
Number of antiarrhythmic drugs before ablation, 
median (IQR)
1.0 (1.0–2.0) 1.0 (1.0–2.0) 1.0 (1.0–2.0) 0.42
Follow ‑up duration, mo, mean (SD) / median (IQR) 42.9 (38.2) / 32 
(12–70)
44.5 (39.1) / 35 
(13–70)
32.1 (30.3) / 14 
(12–60)
0.2 / 0.37
Abbreviations: BMI, body mass index; IQR, interquartile range; IVA, idiopathic ventricular arrhythmia; LVEF, left ventricular ejection fraction; PVC, 
premature ventricular complex; SHD, structural heart disease; VA, ventricular arrhythmia; VT, ventricular tachycardia
TABLE 2 Ablation procedure details
Origin Age, y, 
median (IQR)
Male /
female 
sex, %
Previous 
failed 
ablation, %
nVT or VT / 
total, %
Procedure 
duration, min, 
median (IQR)
Fluoroscopy 
duration, min, 
median (IQR)
RF duration, s, 
median (IQR)
No. of RF 
aplications, 
median 
(IQR)
All,  
n = 103
56 (34–64) 51/49 10 31 75  
(58–95)
5 (0–16) 351  
(191.5–590)
9 (5–15)
LCC,  
n = 50
54  
(31.5–62.8)a
44/56b 8 30 75  
(55–95)
6 (0–16) 348.5  
(154.5–601)
7.5 (4.8–15)
AMC/LCC, 
n = 27
62  
(53–65.5)a,c,d
52/48 14 29 70  
(56.5–90)
4 (0–17.5) 432  
(302.5–544)
12 (6.5–15)
LCC/RCC, 
n = 11
63 (46.5–70) 45/55e 9 45 75  
(62.5–79.5)
0 (0–7) 252  
(180–858.8)
8 (4.5–15)
RCC,  
n = 9
55 (34–58)d 67/33 22 22 120  
(75–170)
6 (0–40) 240  
(160–600)
8 (4–20)
NCC,  
n = 6
27 (20.8–52.8)c 100/0b,e 0 50 65  
(60–95)
2 (0–16) 395  
(252.5–505)
10.5  
(6.8–17.2)
P value 0.04 0.05 0.38 0.46 0.21 0.46 0.48 0.78
Continuous variables are expressed as medians (interquartile ranges, Q1–Q3). Categorical variables are expressed as fractions (%).
a AMC / LCC vs LCC; P = 0.04;  b LCC vs NCC; P = 0.02;  c AMC / LCC vs NCC; P = 0.02;  d AMC / LCC vs RCC; P = 0.04;
e LCC / RCC vs NCC; P = 0.04
Abbreviations: AMC, aorto ‑mitral continuity; LCC, left coronary cusp; NCC, noncoronary cusp; nVT, nonsustained ventricular tachycardia; RCC, right 
coronary cusp; RFA, radiofrequency ablation; VT, ventricular tachycardia; others, see TABLE 1
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(FIGURE 2). The ZF was used in 35% of all proce‑
dures in the registry (36 patients), with increas‑
ing preference in recent years. The least common 
ablation method was conventional ablation with‑
out 3D ‑EAM (11 patients).
The procedure duration was the shortest with 
the ZF method (median, 60.0 minutes; IQR, 
45.0–73.5; P <0.001), which showed a trend 
towards the  lowest number of RFA applica‑
tions as compared with the conventional and 
3 ‑dimensional fluoroscopy / coronary angiog‑
raphy techniques (FIGURE 3). The fluoroscopy du‑
ration was the longest for conventional abla‑
tion as compared with both 3D ‑EAM approaches 
(TABLE 3). The short‑ and long ‑term success rates 
were the highest with ZF (86% and 88%, respec‑
tively), although the difference between ZF and 
other techniques was not significant (TABLE 3). 
The conventional ablation was associated with 
The total number of PVCs recorded on 24 ‑hour 
Holter monitoring decreased significantly from 
baseline to the long ‑term follow ‑up from 19 670 
(IQR, 11 688–29 907) to 96 (1–1566) (P <0.001) 
in the entire sample. There were no differences in 
degree of PVCs reduction with respect to IVA or 
SHD presence and aortic cusp location.
There were no differences between the patients 
with long ‑term treatment success and those with 
treatment failure in all parameters but the left 
atrium size at baseline, which was significantly 
larger in the latter group (38 mm vs 44 mm, re‑
spectively, P = 0.006).
Ablation technique and procedure success There 
were no differences in clinical characteristics 
between the 3 compared techniques (TABLE 3). 
The most commonly used ablation technique 
was 3D ‑EAM with fluoroscopy (56 patients) 
60
80
100 ALL 
ALL without AAD
NCC
RCC
LCC/RCC
AMC/LCC
LCC
Long-term procedural successShort-term procedural successAcute procedural success
%
FIGURE 1 Ventricular arrhythmia origin and ablation success. Acute, short ‑term, and long ‑term success rates after ablation of premature of 
ventricular complexes (PVC) and ventricular tachycardia (VT) with and without antiarrhythmic drug administration. Results are shown for the enitre 
study group including 103 patients, also by PVC / VT location. 
Abbreviations: AAD, antiarrhytmic drug; others, see TABLE 2
TABLE 3 Clinical characteristics of patients and outcomes depending on the ablation technique
All Conventional ablation 3D ‑EAM + F 3D ‑EAM + ZF P value
Age, y, median (IQR) 56 (34–64) 45 (40.5–61.5) 57 (32.5–63) 59 (42.2–68) 0.32
Women, % 48.5 36.4 50 50 0.69
Hypertension, % 61.2 63.6 53.6 72.2 0.19
Insulin ‑dependent diabetes, % 3.9 0 5.4 2.8 1.00
BMI, kg/m2, median (IQR) 26 (23; 31) 25 (23.2–26.8) 26.5 (23–32) 26 (24–28.2) 0.74
Fluoroscopy duration, min, median (IQR) 5 (0–16) 17.5a,b (15.5–20.2) 9.5b,c (5–19) 0a,c (0–0) <0.001
Short ‑term treatment success, % 81 73 80 86 0.72
Long ‑term treatment success, % 86 82 86 88 0.84
a Conventional ablation vs 3D ‑EAM + ZF; P <0.001  b Conventional ablation vs 3D ‑EAM + F; P = 0.04   c 3D ‑EAM + F vs 3D ‑EAM 
+ ZF; P <0.001
Abbreviations: 3D ‑EAM, 3 ‑dimensional electroanatomical mapping; BMI, body mass index; F, fluoroscopy; ZF, zero fluoroscopy; others, see TABLE 1
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a small (about 4 mm) margin scar within the ab‑
lated LCC visible on the MRI, yet undetected on 
echocardiography. However, an NNC thickening 
was identified on echocardiography that was not 
seen on MRI. Except for the scar seen in the MRI, 
the patient only had insignificant mild aortic re‑
gurgitation during the 9 ‑year follow ‑up.
Two patients had moderate aortic steno‑
sis at baseline. There was no progression to se‑
vere aortic stenosis in either short‑ or long ‑term 
follow ‑up. The aortic valve area and mean aor‑
tic gradient did not increase significantly in ei‑
ther of them.
There were 13 cases with suspected PVC‑
‑induced cardiomyopathy. Of those, LVEF im‑
proved after successful ablation in 6 patients, 
and remained low without improvement even af‑
ter successful ablation in 7 patients, which sug‑
gests another mechanism for cardiomyopathy. 
The median values of LVEF at baseline, short‑ 
and long ‑term follow ‑up with regard to the ab‑
lation outcome are presented in Supplementary 
material, Table S2.
Other complications There was a single case of 
postablation pseudoaneurysm, which was treated 
the lowest success rate (nonsignificant) and 
the longest duration as compared with 3D ‑EAM 
(significant difference as compared with ZF).
Complications Postablation echocardiography find-
ings No major pathologies in the aortic or mitral 
leaflets and aortic root were observed (FIGURE 4). 
No moderate / significant aortic stenosis / regur‑
gitation or leaflet perforations were observed af‑
ter ablation.
Clinically insignificant aortic valve cusp degen‑
eration (usually marginal cusp thickening or fibro‑
sis, less often mild aortic regurgitation) was ob‑
served in 16% of patients. Mild / moderate thick‑
ening of the aortic valve was shown in 13 patients, 
whereas 3 patients had minor complications of 
mild aortic regurgitation. There was no correla‑
tion between mild / moderate aortic thickening, 
mild aortic regurgitation, the ablation cusp tar‑
get, and ablation details.
Six patients had echocardiography ‑based in‑
dications for the MRI. It excluded suspected left 
ventricular noncompaction cardiomyopathy in 1 
case and did not confirm moderate aortic leaflet 
thickening observed by the echocardiographers 
in 5 remaining cases. One of these patients had 
3-dimensional zero fluoroscopy ablation54%
35%
11%
Conventional ablation
3-dimensional fluoroscopy / coronarography
FIGURE 2 Distribution 
of ablation techniques
FIGURE 3 Ablation technique and treatment outcomes. Procedure duration and number of radiofrequency ablation applications are shown for 
different ablation techniques. All variables are presented using box plots showing medians and interquartile ranges.
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aortic valve injury may be caused by the catheter 
tip as it is passed through the valve, by RFA appli‑
cation in the aortic leaflet area, or by cusp com‑
pression with the catheter during its prolonged 
placement in the left ventricle.
The risk of valvular injuries during aortic ret‑
rograde approaches potentially correlates with 
procedure duration, the number of RFA appli‑
cations, and passages through the aortic valve, 
being seemingly higher in children and adoles‑
cents with smaller outflow tract diameters.10 Ols‑
son et al10 analyzed 179 patients in whom retro‑
grade aortic approaches were used. Clinically in‑
significant mild aortic insufficiency was report‑
ed in 2 patients.
Our study is the first to evaluate targeted echo‑
cardiographic assessments after RFA of aortic 
cusp VA. After a median observation period of 
about 32 months, we found no significant aortic 
leaflet or aortic root pathology in follow ‑up echo‑
cardiography. The MRI was done in 6 patients to 
verify echocardiographic findings. It confirmed 
a single small scar on an ablated aortic cusp as 
the only identified abnormality. Clinically insig‑
nificant degeneration of the valve cusps found 
in 16% of patients did not correlate with proce‑
dure duration or number of RFA applications, but 
may have been related to aging, as there was lit‑
tle association between cusp ablation target and 
degenerative changes. One patient was referred 
for MRI due to moderate thickening of the aor‑
tic cusp. Even though the MRI could not confirm 
it, it revealed a marginal scar on an ablated cusp 
instead, which had no negative effect seen in a 
9 ‑year follow ‑up, except for the mild aortic regur‑
gitation. This shows that echocardiography may 
not be suitable for detecting subtle aortic cusp 
changes such as postablation scars. Doppler tech‑
niques enable tracking of newly developed aortic 
regurgitation which might reflect injured cusp re‑
traction and subsequent scar formation. It may 
be useful for screening for potential ablation‑
‑induced leaflet perforation or for monitoring of 
surgically (FIGURE 4). There were no other vascu‑
lar access complications, no cases of MI, throm‑
boembolism, tamponade, or conduction disor‑
ders including ablation ‑induced atrioventricular 
block. One patient had a pacemaker implanted 2 
days after ablation, yet the indication (paroxys‑
mal third ‑degree atrioventricular block) had been 
established prior to ablation. One woman expe‑
rienced a vasovagal reaction with transient ele‑
vation of ST ‑T segment in leads II, III, aVF dur‑
ing LCC / RCC ablation. Her symptoms resolved 
spontaneously with no adverse sequelae. Subse‑
quent angiography revealed no pathologies with‑
in the coronary arteries.
Concomitant arrhythmias Additional substrates 
were identified in 12 out of 103 patients (12%). 
These were atrioventricular nodal reentry tachy‑
cardia, paroxysmal atrial tachycardia, and sepa‑
rate focal areas of VA originating from RVOT (n 
= 8), RV (n = 1), and left ventricle (n = 2). All ad‑
ditional substrates were ablated during the same 
procedure.
DISCUSSION Main findings This is the first large 
prospective multicenter analysis of safety and 
very long ‑term clinical and echocardiographic out‑
comes (median follow ‑up of 32 months; IQR, 12–
70) after ablation of VAs originating from aortic 
cusps. The study revealed for the first time that 
RFA could be performed safely and successful‑
ly in the sensitive aortic cusp area, even without 
fluoroscopy and ablation of additional arrhyth‑
mia substrates.
Echocardiographic complications No data have 
been published so far on targeted echocardio‑
graphic assessment after RFA of the aortic cusp, 
although this procedure is considered high ‑risk 
for valve / aortic root damage. Serious complica‑
tions following ablation, such as aortic regurgi‑
tation or aortic leaflet perforation are likely, al‑
though reluctantly reported.9,10 The iatrogenic 
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complications potentially associated with close 
proximity of the ablation catheter to the aor‑
tic root, coronary ostia and conduction system. 
Only one case of transient vasovagal reaction 
was observed with no negative consequences. 
There were no cases of cardiac tamponade. One 
patient required surgical intervention due to vas‑
cular access ‑related pseudoaneurysm. One ‑third 
of ablations in the registry were performed via 
the ZF approach.
Ablation outcomes Our registry study has accu‑
mulated the largest database of VA ablation pro‑
cedures in aortic cusps with echocardiograph‑
ic follow ‑up to date. Our database includes over 
100 patients who underwent RFA at 10 Polish 
electrophysiology centers over 12 years. The abla‑
tions were performed mostly by experienced op‑
erators, which increases data homogeneity in sta‑
tistical comparisons. Previous studies were car‑
ried out in significantly smaller patient popula‑
tions.1,2,5,7,12 So far, there is no data on aortic cusp 
ablation in SHD. Our data shows comparable pro‑
cedure outcomes in patients with or without SHD 
(87% vs 80% in a long ‑term follow ‑up, P = 0.62) 
with very few procedure ‑related complications, 
even when preexisting aortic stenosis was pres‑
ent. There were no differences in procedure out‑
comes relative to VA cusp location.
Our registry ablation procedures were per‑
formed by experienced operators, resulting in 
high treatment success rates (acute 93%, long‑
‑term 86%) along with relatively short median 
procedure duration (75 minutes), very short flu‑
oroscopy duration (5 minutes), and even com‑
plete elimination of fluoroscopy in one ‑third of 
patients. In a recently published retrospective co‑
hort study, the mean procedure duration in IVA 
aortic cusps ablation and the fluoroscopy dura‑
tion were considerably longer (178 minutes and 
27 minutes, respectively) with comparable long‑
‑term outcomes.2
Ablation technique Compared with the conven‑
tional and 3 ‑dimensional fluoroscopic techniques, 
the ZF approach, similarly to Zhu et al,5 reduced 
the total procedure duration, thus maintaining 
the high RFA success rate. Modern 3D mapping 
technology and operator learning curve seem to 
shorten the procedure and fluoroscopy duration 
with acute and long ‑term RFA success rates com‑
parable with (but not better than) conventionally‑
‑guided procedures.
According to the guidelines, unlike patients 
with VA of RVOT origin,16 those with VA of LVOT 
origin including aortic cusp locations should only 
be treated by RFA after previous failure of anti‑
arrhythmic therapy as the procedure is consid‑
ered high ‑risk. However, VA constitutes a sig‑
nificant clinical problem and medical treatment 
is often insufficient, especially in patients with 
poor compliance.6,7 There is no universal best 
choice treatment for VA. Due to the rare but se‑
rious complications of aortic cusp ablation,2,4,5,14 
the deterioration of preexisting valvular diseas‑
es. Such deterioration of echocardiographic pa‑
rameters, which could indicate severe aortic dys‑
function after aortic cusp ablation, was not seen 
in our 2 patients with preexisting moderate aor‑
tic stenosis. In both cases, long ‑term follow ‑up 
confirmed continued success.
In our registry, about half of suspected PVC‑
‑induced cardiomyopathy cases were ruled out fol‑
lowing successful ablation, with no LVEF reversal 
in the follow ‑up. The true PVC ‑induced cardiomy‑
opathy rate was rather low (6%) as compared with 
other studies which reported the incidence rates 
up to 40% in selected groups of patients at highly 
specialist centers with experienced personnel.11
Aortic cusp ventricular arrhythmia origins The prev‑
alence rates of aortic cusp VA origins are in 
keeping with previous studies.1,4,7,12 The LCC 
was the most frequent location, followed by 
AMC / LCC, LCC / RCC, and RCC. The NCC was 
the rarest ablation target, found in 6% of sub‑
jects, only young males with frequent complex ar‑
rhythmias and high ablation success rate reach‑
ing 100%. Patients with AMC / LCC VA cusp lo‑
cations were generally older than patients with 
other VA cusp targets except for the LCC / RCC. 
Procedure duration was longer in patients under‑
going RCC ablation. Double tachycardia was de‑
tected during the EP study in only 2% of patients. 
In 10% of cases, additional focal VA was encoun‑
tered, usually within the RVOT. Interestingly, aor‑
tic root could also be a substrate for the ablation 
of other arrhythmias like those in the Wolff–Par‑
kinson–White syndrome, atrioventricular nod‑
al reentrant tachycardia, and atrial tachycardia. 
Unlike the IVA, the RCC and NCC are targeted 
more frequently.13
Other complications Although IVA ablation com‑
plications are rare, injuries to the coronary arter‑
ies, aortic root, and conduction system have been 
reported. Coronary angiography has tradition‑
ally been recommended before aortic cusp cath‑
eter ablation to ensure a safe distance to coro‑
nary arteries.1
Chronic left main artery occlusion has been 
reported as a complication of RFA of idiopathic 
left VT.14 In a retrospective cohort study of idio‑
pathic PVC ablation outcomes in 1185 patients, 
including aortic cusp ablation in 15% of proce‑
dures,2 the overall complication rate was 5.2% 
including the most frequently reported vascular 
access complications (1.3%), tamponade (0.8%) 
and atrioventricular block (0.1%). In another co‑
hort study by Oomen et al,15 5 (3.8%) of 131 pa‑
tients undergoing ablation due to symptomatic 
VA (13% in aortic cusps) had nonfatal complica‑
tions including 3 tamponades (not during aortic 
cusp ablation), 1 case of third ‑degree atrioven‑
tricular block requiring pacemaker, and 1 case of 
abdominal hematoma.
Our registry included only the patients with 
VA ablation target in aortic cusps. There were no 
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RFA should only be considered in particularly dif‑
ficult clinical scenarios (highly symptomatic, life‑
‑threatening VA), and patients should be referred 
directly to experienced electrophysiology centers, 
thus shortening, or even skipping medical treat‑
ment attempts. Using a computer ‑assisted semi‑
‑automatic system, which can be implemented in 
commonly used ECG recorders, described else‑
where by our study group, may additionally facil‑
itate clinical decision ‑making of noninvasive car‑
diologists regarding the VA site of origin.7
Study limitations One of the study limitations 
is the technique used for aortic root assessment 
before and after ablation. Since the beginning 
of the registry in 2005, in the majority of ini‑
tial assessments, echocardiography has been 
used. The follow ‑up assessments have also been 
echocardiography ‑based; however, minor chang‑
es can be better detected with modern devices, 
causing potential study bias. Echocardiography 
is not a reference technique for the detection of 
subtle cardiac changes; however, due to limited 
access and high cost, MRI could not be performed 
in all patients.
Other limitations are a relatively large number 
of patients lost to follow ‑up and patients with in‑
complete clinical data (Holter monitoring or echo‑
cardiography) which were excluded from the base‑
line study group. This was mainly due to the very 
long follow ‑up, missing contact details, patient 
deaths or inability to perform all required tests. 
Also due to the long follow ‑up, the final visits 
took place at different time points (follow ‑up 
IQR, 12–70 months).
Conclusions Ablation of PVCs / VT within aor‑
tic cusps is safe and effective in both short‑ and 
very long ‑term follow ‑up. The ZF approach is fea‑
sible and safe; however, better expertise and more 
imaging modalities are required.
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